Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-11 - Apixaban
Description
The participating funds aim to conclude discount contracts pursuant to Section 130c (1) SGB V with all suitable pharmaceutical companies for the active substance Apixaban. The contract is concluded within the framework of the Open-House-Originale procedure of the participating funds: Individual negotiations on contract terms are not conducted, and uniform conditions apply. The participating health insurance funds do not guarantee exclusivity to individual contracting partners. The contract duration is a maximum of 24 months, starting on 01.10.2026. The contract ends no later than 30.09.2028, regardless of the date of contract conclusion. In the event of patent expiry/expiry of market exclusivity before the aforementioned end date, the contract automatically expires at the end of the month of patent expiry/market exclusivity. Joining this Open-House-Originale procedure is possible at any time during the contract period. All further information can be found in the participation and contract documents.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glycopyrronium + Indacaterol, ATC R03AL12 für die Zeit 01.01.2027 - 31.12.2028
DAK-GesundheitGermanyPharmaceutical productsDeadline in 719 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mometason (ausschl. in der Dafo. Lösung), ATC D07AC13 f. d. Z. 01.01.2027-31.12.2028 (zzgl. V.-Option 1x12 M)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pamidronsäure, ATC M05BA03 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. V.-Option 1x12 Monate)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Morphin (ausschl. in der Dafo. FTA + HKP + SMT), ATC N02AA01 f. d. Z. 01.01.27-31.12.28, zzgl V.-Option 1x12M
DAK-GesundheitGermanyPharmaceutical productsDeadline in 1,084 daysPublished on Nov 16, 2026